Introduction {#S0001}
============

Haemophilia, a hereditary congenital chronic coagulopathy, entails deficits in the coagulation factors and presents spontaneous or trauma-related muscle or joint bleeding. Its treatment consists of the intravenous administration of the deficit factor in two ways: on-demand or in prophylaxis.[@CIT0001],[@CIT0002] Prophylactic treatment is currently considered as the "gold standard" because it reduces or prevents the presence of bleeding and delays the onset of joint diseases.[@CIT0003]--[@CIT0005] The following of treatment is essential to maintain adequate control of the disease and lead a normal life. However, patients do not always follow this recommendation, generating adherence problems and treatment non-efficacy.

Adherence involves a dynamic and multidimensional process.[@CIT0006] That is, it varies over time and depends on multiple factors. The World Health Organization (WHO) defines it as "extent to which a patient's behaviour coincides with the prescribed health care regimen as agreed through a shared decision-making process between the patient and the health care provider, both from the point view of habits or lifestyles recommended, as well as, prescribed pharmacological treatment"[@CIT0007] It is a problem for not only the patient (ie, treatment ineffectiveness affects their quality of life) but also the entire population, as well as for current and upcoming biomedical advances.

The adherence rates associated with haemophilia vary from 44% to 87% depending on the studies and methods used.[@CIT0008]--[@CIT0012] The first studies[@CIT0008],[@CIT0013]-[@CIT0015] showed adherence levels between 45% and 60% but with a great variety of methods that were impossible to replicate. Duncan et al.[@CIT0016],[@CIT0017] developed two standardised self-evaluation questionnaires that sought to measure the different components of adherence and the degree of total adherence among patients with haemophilia following a prophylactic treatment or on-demand treatment. Its purpose was to measure the adherence to the instructions given by the professional based on the treatment prescribed (pharmacological).

Recent studies refer to the importance of the assessment of adherence regarding patients' perceptions or beliefs about their need for treatment, attitudes and motivation, relationships with professionals, and active participation in decision-making.[@CIT0018]--[@CIT0022] Thus, the aim of this study was to build a multidimensional questionnaire that included aspects regarding compliance (ie, following the prescribed guidelines, only administer the deficit coagulation factor) and adherence (ie, patient awareness of the disease or the mental representation of their situation, therapeutic alliance, knowledge about the management of relevant clinical processes and consequences of the disease). Both concepts imply that the patients understand the most appropriate behaviour to control their illness and prevent risks, in addition, it is necessary to maintain a positive and regular relationship with their doctor because all of that will encourage them to take care of themselves. Knowledge of conflicts or difficulties in these areas will facilitate interventions to resolve adherence problems and provide treatment continuity and effectiveness.

Materials and Methods {#S0002}
=====================

Study Design {#S0002-S2001}
------------

A cross-sectional study was conducted with a group of patients with haemophilia (PWH) aged between 15 and 64 years.

Patients {#S0002-S2002}
--------

A total of 146 patients with haemophilia (A and B) were recruited for this study of several Haemophilia Treatment Centers (HTC) in Spain. The patients had different degrees of haemophilia (mild, moderate, and severe) and were participating in prophylactic or on-demand treatment. The recruitment was performed through a personal interview. The time spent on it was between 20 and 25 mins for each patient.

Ethics and Consent to Participate {#S0002-S2003}
---------------------------------

The Ethics Committee of the University of Murcia (School of Medicine) approved this study and the Spanish Agency of Medicines and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios; AEMPS. Study No-EPA) approved and classified this study as No-EPA (Non-post-authorization observational study). The participants signed an informed consent document (following the Declaration of Helsinki, 1975). The parent or legal guardian of any patient under the age of 18 years provided a written informed consent.

Procedure {#S0002-S2004}
---------

The literature was reviewed using the PUBMED, PsycINFO, MEDLINE, and SCOPUS databases. The keywords used were "adherence questionnaires", "psychometric properties", "haemophilia", and "validation"; all keywords were combined with the Boolean operators AND and OR. Given the purpose of our study, our article analysis led us to the most representative dimensions: disease awareness (DA), sequelae knowledge (SK), difficulties with treatment (DT), doctor--patient relationship (DPR), and haemorrhagic processes treatment (HPT). See [[Appendix 1](https://www.dovepress.com/get_supplementary_file.php?f=233601.zip)]{.ul} for detailed definitions.

In addition, 10 questions addressed basic haemophilia concepts such as disease characteristics, treatment types, complications, and preventive measures to follow its evolution to assess patients' disease knowledge.

In the first version of the Haemo-Adhaesione questionnaire, 136 items were developed and sent to five expert evaluators in the field of haemophilia with 20 years of experience working in HTCs for an external trial. Each expert individually reported their agreement with the items via qualitative and quantitative judgements using a Likert scale ranging from 0 to 4. In addition, these items were presented and discussed with a group of patients (n = 12). The opinion of the patients was recorded with regard to the difficulty associated with understanding the concepts presented in the items, how patients interpreted each item, and their degree of agreement with the items representing the behaviours to be measured. Item comprehension was also evaluated based on the educational level of the patients (minimal or secondary school level \[15 or 16 years\]).

A congruency analysis was performed, and the items with the highest level of agreement were selected. The inter-rater agreement ranged between 0.90 and 1.00. Based on the analysis of both experts and patients, 65 items were eliminated. The pilot scale that was administered consisted of 61 items: 16 DA items, 6 SK items, 20 DT items, 7 DPR items, and 11 HPT items, as well as 10 items on knowledge of the disease.

The questions were posed to patients receiving prophylaxis and those receiving on-demand treatments because both should follow specific and scheduled instructions according to their doctor's prescriptions but in different ways.

Measurements {#S0002-S2005}
------------

Other adherence measures were used to validate the Haemo-Adhaesione as follows:

VERITAS-Pro[@CIT0016],[@CIT0032] is a validated adherence measure for prophylactic treatment. This scale consists of 24 items and six subscales: time, dose, plan, remember, skip, and communicate. The potential scores range from 24 to 120, where a low score indicates greater adherence. The estimated cut-off is 38 points, considering the scale's total score.

VERITAS-PRN[@CIT0017] is a validated adherence measure for on-demand treatment. This scale consists of 24 items and six subscales: time, treatment, dose, plan, remember, and communicate. The potential scores range from 24 to 120, and a low score indicates greater adherence. The estimated cut-off is 38 points, considering the scale's total score.

Statistical and Psychometric Analyses {#S0002-S2006}
-------------------------------------

Descriptive statistics and item discrimination indices were calculated. To determine metric quality, an interval (0.3--0.7) was used, where a value of 0.30 was used to eliminate the item.

To maintain a balanced number of items for each dimension, the items were classified by the discrimination index. The least discriminative items and those whose wording represented slightly different aspects of the dimension than those intended were eliminated completely.

The internal consistency of the scores for each dimension was assessed with Cronbach's alpha coefficient.

The scale structure was tested with a multidimensional version of the rating scale model.[@CIT0023] The items followed the specified model if their infit and outfit statistics fell within the interval \[0.6--1.4\].

A convergent validity study was performed to assess the correlations between the dimensions of the constructed scale and the VERITAS-Pro and VERITAS-PRN scales. In addition, empirical validity was determined via Student's *t*-test and an ANOVA. The effect size (ES) was assessed using Cohen's d standardised mean difference (where small, medium, and large ESs are 0.20, 0.50, and 0.80, respectively) or ω^2^ (where small, medium, and large values are 0.01, 0.06, and 0.14, respectively). All analyses were performed using SPSS v. 19.0 and ConQuest v. 4.0.[@CIT0024]

Results {#S0003}
=======

The age of the patients ranged from 15 to 64 years old (Mean = 40.0; SD = 11.5). A total of 120 (82.2%) patients had type A haemophilia, and 26 (17.8%) had type B haemophilia; 10 cases (6.8%) were mild, 46 cases (31.5%) were moderate, and 90 cases (61.6%) were severe. A total of 62 patients (42.5%) were receiving on-demand treatment, and 84 (57.5%) were receiving prophylaxis. In addition, 11 (7.5%) patients developed an inhibitor, 93 (63.7%) had a family history of haemophilia, 92 (63%) had hemarthrosis, 123 (84.2%) developed a joint disease, 19 (13%) needed an orthotic, and 89 (61%) had co-infections with HCV, HIV, or both. See [Table 1](#T0001){ref-type="table"}.Table 1Sociodemographic and Clinical Characteristics of the Patientsn%MeanSDRangeAge40.011.5\[15--64\]Type of hemophilia Hemophilia A12082.2 Hemophilia B2617.8Severity of hemophilia Mild106.8 Moderate4631.5 Severe9061.6Treatment Prophylaxis6242.5 On demand8457.5 Days of treatment1.21.5\[0--7\]Inhibitor Yes117.5 No13592.5Family History Yes9363.7 No5336.3Hemarthrosis Yes9263.0 No5437.0Arthropathy Yes12384.2 No2315.8Orthosis Yes1913.0 No12787.0Co-infections Yes8961.0 No5739.0

Item Analysis {#S0003-S2001}
-------------

[Table 2](#T0002){ref-type="table"} shows the means, standard deviations, and homogeneity indices of the dimensions of the proposed adherence scale. The items that were selected for the final scale based on the statistics applied and the expert judgement of the research team appear in bold. We attempted to maintain a balance between the five dimensions of the scale so that the DA dimension was composed of six items, the SK dimension was composed of four items, the DT dimension was composed of five items, the DPR dimension was composed of five items, and the HPT dimension was composed of five items. The final scale appears in [[Appendix 2](https://www.dovepress.com/get_supplementary_file.php?f=233601.zip)]{.ul}. The knowledge of the disease dimension was not a part of the final scale because between 99% and 100% of patients answered all items correctly.Table 2Mean (SD) in Each Category of Total Scores, Mean (M), Standard Deviation (SD) and Homogeneity Index of the ItemsADimensionCategoriesMSDr~jx~NeverSometimesRegularAlwaysAwareness of Illness **Item 1(inv)32.3(2.2)29.4(3.1)26.0(4.3)21.6(3.8)1.800.720.45** Item 226.8(4.6)27.6(3.6)31.2(3.7)31.0(2.1)1.250.790.22 Item 328.9(5.3)28.7(4.3)28.8(2.9)27.5(4.0)1.200.77−0.23 Item 4(inv)31.1(2.7)28.2(4.4)28.8(3.8)27.4(4.0)1.680.74−0.06 Item 531.0(2.8)26.3(4.8)29.4(3.6)--2.730.480.16 Item 622.0(--)26.4(5.4)27.7(4.3)29.6(3.6)2.490.650.14 Item 730.0(4.2)25.7(4.7)28.5(3.0)30.0(3.8)2.250.830.17 **Item 8(inv)30.6(3.6)28.1(3.0)23.1(4.6)19.0(---)2.330.670.42** **Item 9(inv)31.3(4.5)29.9(3.0)26.9(3.6)22.6(5.7)1.660.710.39** **Item 10(inv)**--**30.1(3.2)27.4(3.7)21.3(6.6)2.520.580.36** **Item 11(inv)31.3(2.7)27.3(3.4)24.3(5.6)20.0(---)2.320.650.47** **Item 12(inv)33.0(2.9)30.2(3.1)28.2(2.6)23.3(5.0)1.410.810.45** Item 13(inv)31.5(2.4)28.1(3.1)24.7(3.4)22.8(6.6)2.140.840.48 Item 14(inv)--29.8(3.8)28.5(3.7)24.5(5.5)2.320.630.17 Item 15(inv)--28.8(4.2)28.4(3.3)25.0(2.7)2.820.430.00 Item 16(inv)--28.7(4.2)29.3(3.7)25.8(4.0)2.750.52−0.07Sequelae Knowledge **Item 179.0(2.8**)**10.6(2.4)12.8(2.1)15.0(2.2)2.690.700.34** **Item 187.5(0.7)11.9(2.3)13.0(2.5)15.2(2.1**)**2.530.560.31** **Item 199.8(2.4)10.0(2.0)13.9(1.9)15.7(1.8)2.380.800.49** **Item 209.0(1.8)10.9(2.3)14.3(1.8)15.8(1.8)2.260.820.48** Item 21(inv)15.5(2.5)13.4(2.1)11.8(2.0)10.8(2.6)2.430.720.25 Item 22(inv)15.5(2.7)14.4(2.3)13.4(2.2)9.9(1.2)2.040.780.15Treatment Difficulties **Item 2337.6(4.7**)**43.1(4.1)43.4(5.0)47.2(4.6)1.470.910.29** **Item 2434.5(8.0)39.5(4.5)42.0(3.6)46.3(4.4)2.210.780.46** Item 2530.0(---)40.0(7.8)40.0(3.9)44.0(4.9)2.750.540.25 Item 2639.1(4.9)42.6(3.5)41.0(4.3)44.4(5.4)2.320.940.09 **Item 2737.0(6.8)37.9(3.8)40.8(3.8)45.0(4.6)2.490.800.39** Item 2839.1(7.7)39.8(6.2)40.2(4.7)44.1(4.5)2.590.880.17 Item 2937.4(5.3)42.1(5.0)42.1(4.7)45.6(4.6)2.120.790.20 Item 3043.0(5.0)42.2(5.7)42.5(4.6)45.8(4.8)1.800.840.04 Item 31(inv)--45.1(6.0)41.8(4.1)47.0(--)2.400.500.20 Item 32(inv)--44.7(6.2)42.2(4.0)41.0(3.8)2.340.600.15 Item 33(inv)--44.7(5.6)42.0(3.9)37.9(2.8)2.470.620.26 **Item 34(inv)45.0(4.2)40.9(4.9)37.0(6.3)40.8(7.2)2.480.740.28** Item 35(inv)43.0(6.3)45.1(4.4)41.7(3.6)41.2(3.6)2.040.91−0.08 Item 36(inv)44.4(5.1)40.4(4.4)40.0(5.0)39.4(2.0)2.600.710.21 Item 3743.3(6.8)38.8(6.7)39.3(5.0)43.5(4.9)2.690.83−0.06 Item 38(inv)44.9(6.5)42.5(3.8)37.4(2.3)41.0(7.6)2.270.630.17 Item 3938.6(6.6)41.6(5.4)43.4(4.3)45.3(4.2)1.910.970.23 Item 4039.1(6.5)42.2(4.5)43.7(4.7)44.7(4.7)1.860.980.14 Item 41(inv)44.0(4.8)40.3(4.9)31.5(7.8)--2.790.490.26 **Item 4234.3(5.3)40.8(3.7)41.4(3.9)44.4(4.7)2.560.840.33BDimensionCategoriesMSDr~jx~** **0123**Doctor-Patient Relationship **Item 439.2(2.8)10.2(2.5)12.8(2.2)16.5(1.6)1.630.800.54** Item 4412.3(1.5)9.3(2.7)10.5(2.2)14.6(2.7)2.270.720.38 **Item 459.2(1.1)10.6(2.3**)**15.7(1.9)--2.250.560.62** **Item 467.0(---)8.8(1.5)11.6(1.9)15.8(1.8)2.030.770.73** Item 4712.9(3.1)11.0(3.0)12.3(2.8)16.3(2.9)0.820.78−0.23 **Item 4814.0(---)8.4(1.5)10.7(2.1**)**15.1(2.2)2.250.690.59** **Item 497.8(1.7)9.3(1.5)12.7(2.1)15.5(2.0)1.870.860.69**Hemorrhagic Process Treatment Item 5018.2(4.4)22.9(6.9)21.2(5.4)--2.680.63−0.03 Item 5117.0(3.8)21.5(5.1)22.2(6.0)20.7(5.8)1.930.93−0.16 **Item 5212.6(5.6)17.3(4.1)22.1(3.9)23.9(4.5)2.080.980.49** Item 5318.0(4.8)18.9(5.0)24.5(3.1)26.8(3.5)1.281.050.46 **Item 5412.9(6.1)15.9(3.1)20.8(3.8)24.5(4.0)2.190.970.61** Item 55(inv)23.2(4.4)23.3(4.4)18.3(4.0)15.3(5.8)2.061.180.37 **Item 568.0(4.1)13.9(3.4)17.6(3.0)23.3(4.2)2.580.780.62** **Item 5713.8(5.4)18.6(4.0)22.4(3.7)26.2(3.6)1.720.980.60** Item 5817.4(4.9)20.2(4.6)24.8(3.2)27.4(4.2)1.131.020.51 **Item 5915.8(4.2)15.8(4.4)22.1(2.8)25.4(3.6)1.951.020.62** Item 604.5(0.7)16.5(5.6)19.7(4.7)22.5(5.0)2.580.690.34[^1]

Haemo-Adhaesione scores {#S0003-S2002}
-----------------------

[Table 3](#T0003){ref-type="table"} presents the descriptive statistics and the alpha coefficients of the five dimensions. No floor effect was observed with regard to any dimension, although ceiling effects were found for DT (28.1%) and DPR (17.1%), which might have partially reduced the reliability of the scores. All dimensions obtained reliability coefficients above 0.70, except for the DT dimension, which had a relatively low value (0.56); however, this value was noticeable depending on the number of items used to obtain it.Table 3Descriptive Statistics and Reliability Coefficients of the Five Dimensions of the Haemo-AdhaesionelMSDRangeFloor EffectCeiling EffectMinMaxαAI612.12.7\[3--17\]0(0%)0(0%)0180.72SK49.92.3\[1--12\]0(0%)41(28.1%)0120.71DT511.22.5\[1--15\]0(0%)8(5.5%)0150.56DPR510.02.9\[4--15\]0(0%)16(11%)0150.85HPT510.53.7\[0--15\]0(0%)25(17.1%)0150.83Total2553.76.6\[24--68\]0(0%)0(0%)075--[^2]

The correlations between all dimensions were significant, except for DA, which was not correlated with the other scale dimensions. The correlations of the dimensions of the Haemo-Adhaesione scale with the VERITAS-Pro scale were significant and negative, given that the latter scale assesses adherence in the opposite direction. In this sense, DA was significantly correlated with dose (p \< 0.05), plan (p \< 0.001), and the total score (p \< 0.05). SK was significantly correlated with plan (p \< 0.05). DT was significantly correlated with plan (p \< 0.05), remember (p \< 0.01), skip (p \< 0.01), communicate (p \< 0.01), and the total score (p \< 0.001). DPR was significantly correlated with remember (p \< 0.01), skip (p \< 0.05), communicate (p \< 0.001) and the total score (p \< 0.05), and the total score was significantly correlated with time (p \< 0.05), plan (p \< 0.001), skip (p \< 0.01), communicate (p \< 0.05), and the total VERITAS-Pro score (p \< 0.01).See [Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"}.Table 4Pearson Correlation Between Dimensions of Adherence ScaleAISKTDDPRSK−0.06TD−0.040.30\*\*\*DPR−0.03−0.31\*\*\*0.17\*HPR−0.200.58\*\*\*0.33\*\*\*−0.38\*\*\*[^3][^4] Table 5Pearson Correlation Between Adherence Dimensions and VERITAS-Pro ScaleAISKTDDPRHPTTotalTime−0.25−0.02−0.19−0.09−0.11−0.28\*Dose−0.30\*0.04−0.20−0.190.10−0.22Plan−0.52\*\*\*−0.36\*−0.27\*0.18−0.20−0.46\*\*\*Remember−0.050.16−0.40\*\*−0.38\*\*0.11−0.23Skip−0.150.05−0.52\*\*−0.31\*−0.04−0.43\*\*Communicate−0.150.18−0.34\*\*−0.49\*\*\*0.17−0.27\*Total−0.31\*0.02−0.47\*\*\*−0.34\*0.02−0.44\*\*[^5][^6]

The Haemo-Adhaesione scale was also negatively and significantly correlated with the VERITAS-PRN scale (see [Table 6](#T0006){ref-type="table"}), except with regard to the DA dimension. The SK dimension was significantly correlated with treatment (p \< 0.05), time (p \< 0.001), plan (p \< 0.001), remember (p \< 0.01), and the total score (p \< 0.001). The DT dimension was significantly correlated with treatment (p \< 0.05), time (p \< 0.001), plan (p \< 0.001), and the total score (p \< 0.001). The DPR dimensions were significantly correlated with time (p \< 0.001) and remember (p \< 0.01). The HPT dimension was significantly correlated with treatment (p \< 0.001), time (p \< 0.001), plan (p \< 0.001), remember (p \< 0.001), and the total score (p \< 0.001). Finally, the total score was significantly correlated with treatment (p \< 0.001), time (p \< 0.001), plan (p \< 0.001), remember (p \< 0.05), and the total VERITAS-PRN score (p \< 0.001).Table 6Pearson Correlation Between Adherence Dimensions and Veritas-PRN ScaleAISKTDDPRHPTTotalTreatment0.01−0.25\*−0.27\*−0.07−0.44\*\*\*−0.45\*\*\*Time0.16−0.58\*\*\*−0.35\*\*0.44\*\*\*−0.78\*\*\*−0.51\*\*\*Dose−0.07−0.03−0.10−0.15−0.02−0.13Plan0.08−0.48\*\*\*−0.36\*\*\*−0.03−0.37\*\*\*−0.48\*\*\*Remember0.03−0.29\*\*−0.080.32\*\*−0.47\*\*\*−0.24\*Communicate0.170.07−0.16−0.13−0.13−0.10Total0.13−0.44\*\*\*−0.44\*\*\*0.10−0.64\*\*\*−0.55\*\*\*[^7]

Structural Validity {#S0003-S2003}
-------------------

To confirm the multidimensional structure of the Haemo-Adhaesione scale, a multidimensional Rating Scale Model was applied. The parameter estimations and fit statistics appear in [Table 7](#T0007){ref-type="table"}. All but items 14 and 15 on the DT dimension were associated with fit statistics within the range expected by the model. The parameter separation index (0.99) was sufficiently high, indicating an adequate separation of the items used to assess treatment adherence across the five specified dimensions. In addition, the categories were in order and sufficiently separated (δ~1~= −1.701, δ~2~= 0.071, δ~3~= 1.629), showing that the number of categories used in this scale worked properly.Table 7Parameter Estimation and Goodness-of-Fit Statistics of Haemo-Adhaesione ScaleItemEstimateErrorOutfitInfitItemEstimateErrorOutfitInfit1(1)0.4510.0800.700.7014(34)−0.5260.1041.521.472(8)−0.6240.0850.750.7615(42)−0.766\*0.1991.681.823(9)0.7190.0800.780.7816(43)0.7880.0830.810.804(10)−1.1270.0880.820.8217(45)−0.5360.0870.590.545(11)−0.6070.0840.770.7618(46)−0.0390.0850.560.576(12)1.188\*0.1870.920.9219(48)−0.5190.0870.640.637(17)−0.7850.1070.821.2920(49)0.306\*0.1710.730.728(18)−0.1590.1011.051.2021(52)0.1300.0941.401.379(19)0.3130.0971.261.3222(54)−0.1480.0951.131.3810(20)0.630\*0.1761.261.3023(56)−1.4730.1040.871.2411(23)1.6710.0911.321.3124(57)1.0270.0911.041.0412(24)0.1890.0971.101.1125(59)0.464\*0.1921.191.2013(27)−0.5680.1051.171.35----------[^8]

Empirical Validity {#S0003-S2004}
------------------

No significant differences were found with regard to any of the dimensions or the total score based on the type of haemophilia.

The patients receiving prophylaxis showed higher DT (ES = 0.37) scores than those receiving on-demand treatment. The latter showed better management with regard to HPT than patients on prophylaxis (ES = −0.51). Patients with moderate haemophilia showed better SK (ES = 0.13) scores than patients with mild or severe haemophilia. In addition, patients with severe or moderate haemophilia showed higher DT (ES = 0.25) scores than those with mild haemophilia, whereas patients with moderate haemophilia showed better HPT management (ES = 0.15).

In general, patients with inhibitors show better DPR (ES = 1.04) scores than those who did not. However, patients with a family history of haemophilia showed more DT (ES = −0.38) than those without. Patients with hemarthrosis showed lower DA (ES = −0.35) scores than those without. Patients with joint disease showed higher SK (ES = 0.98) scores, a worse PMR ratio (ES = −0.59), and better HPT (ES = 1.21) scores. However, patients with co-infections showed better SK (ES = 0.50) and HPT (ES = 0.95) scores. Finally, patients with orthosis showed better PMR (ES = 0.81) scores than those without orthosis. See [Table 8](#T0008){ref-type="table"}.Table 8Mean (SD) of the Dimensions of Veritas-PRNAISKTDDPRHPTTotalType of Hemophilia Hemophilia A12.1(2.6)9.9(2.3)11.3(2.5)10.1(3.0)10.4(3.7)53.8(6.6) Hemophilia B11.7(3.0)9.7(2.3)10.9(2.4)9.7(2.8)11.0(3.6)52.9(6.9)Treatment Prophylaxis12.3(2.8)9.6(2.2)11.7(2.2)\*10.4(3.1)9.5(3.3)\*\*53.6(6.7) On demand11.9(2.6)10.0(2.3)10.8(2.6)9.7(2.9)11.3(3.7)53.7(6.7)Severity Mild11.4(2.9)7.8(3.6)8.2(4.5)11.1(2.9)7.3(4.5)45.8(9.6) Moderate12.3(2.3)10.1(2.3)11.3(2.1)9.6(2.6)11.4(3.8)54.7(6.4) Severe12.0(2.9)9.9(2.0)\*11.5(2.1)\*\*\*10.1(3.1)10.5(3.3)\*\*54.0(5.8)\*\*\*Inhibitors Yes12.2(3.3)9.0(2.3)11.2(3.3)12.7(2.7)\*\*9.1(3.9)54.2(8.3) No12.0(2.7)9.9(2.3)11.2(2.4)9.8(2.9)10.6(3.6)53.6(6.5)Family history Yes12.0(2.6)9.8(2.3)10.9(2.6)\*10.0(3.0)10.4(3.7)53.1(6.6) No12.2(2.8)9.9(2.3)11.8(2.1)10.(2.9)10.7(3.7)54.6(6.7)Hemarthrosis Yes11.7(3.0)\*9.8(2.0)11.1(2.6)10.4(3.0)10.3(3.7)53.3(6.5) No12.6(2.0)9.9(2.7)11.3(2.3)9.5(2.8)10.9(3.6)54.3(6.9)Arthropathy Yes11.9(2.7)10.2(1.8)\*\*\*11.4(2.1)9.8(2.9)\*11.2(3.3)\*\*\*54.5(5.8)\* No13.0(2.6)7.7(3.1)10.4(3.7)11.5(2.9)7.1(3.5)49.8(9.3)Co-infections Yes12.1(2.7)10.5(1.8)\*\*10.8(2.5)9.5(2.6)12.5(3.1)\*\*\*55.4(6.6)\*\* No12.0(2.7)9.4(2.5)11.5(2.5)10.4(3.1)9.3(3.5)52.5(6.5)Orthosis Yes10.6(4.2)9.5(2.2)10.3(3.3)12.0(2.7)\*\*9.4(4.1)51.6(7.7) No12.3(2.3)9.9(2.3)11.4(2.3)9.8(2.9)10.7(3.6)54.0(6.4)[^9][^10]

Discussion {#S0004}
==========

The results obtained showed a high degree of adherence and between 99% and 100% of patients showed adequate knowledge of their haemophilia and its treatment. The degree of adherence found was similar to that in recent studies.[@CIT0011],[@CIT0012],[@CIT0021],[@CIT0022]

The Haemo-Adhaesione scale was valid and reliable for assessing adherence among the Spanish population. Its internal consistency was acceptable for all dimensions, except DT, which might have been because of the number of items used. In addition, a ceiling effect was observed with regard to the dimensions DT and DPR, which indicates that difficulties can be experienced when discriminating between patients.

The Rasch model showed that all items except items 14 and 15 of the DT dimension had a satisfactory fit to the model.

Negative significant correlations were observed with regard to all dimensions and the total scores of the VERITAS-Pro and VERITAS-PRN scales. Adherence among patients with haemophilia is based on not only compliance with the professional's prescriptions but also psychological aspects such as awareness of the disease and the relationship with the professional (the patient shows an agreement and commitment with to his health).[@CIT0018]--[@CIT0022]

All of the Haemo-Adhaesione dimensions were correlated with those of the VERITAS-Pro, except for HPT. Patients receiving prophylaxis showed satisfactory adherence, planned their treatment without omissions, and followed the indications of the professional, with whom they had a positive relationship. They also expressed adequate awareness of their disease due to their behaviours correlated with the advice that professional pointed out in order to manage his disease. Their lack of attention to haemorrhagic processes might be understood based on the finding that their treatment reduces the appearance of these symptoms, thereby decreasing worry. This aspect is important to consider with regard to adherence.[@CIT0028]

All of the dimensions of the VERITAS-PRN were correlated, except for DA. Patients receiving on-demand treatment showed satisfactory treatment adherence. Their lower disease awareness might be conditioned by the low (mild) symptomatology which they typically present. Therefore, some authors[@CIT0025]--[@CIT0027] have warned of the importance of raising awareness and educating these patients to prevent future difficulties because of their lack of attention to their disease.

Significant differences were found with regard to the dimension HPT. Patients receiving on-demand treatment were more likely to adhere than those receiving prophylaxis. This result might be because they felt less secure or protected from the disease and therefore paid more attention to their treatment when symptoms appeared.[@CIT0018]

Patients with moderate haemophilia were more adherent with regard to the dimensions SK and HPT; however, patients with severe symptoms were more adherent with regard to the total score. Patients with severe haemophilia had the highest total score (most adherent). In addition, both cases coincide with a diagnosis of joint disease and the presence of co-infections. Given the mean age of the sample, it is unlikely that many patients with arthropathy and co-infections had not received prophylaxis with their first treatments which have had an impact on adulthood. Although they now receive more effective treatments, joint damage is already established.[@CIT0014],[@CIT0018],[@CIT0019],[@CIT0021],[@CIT0028]

Patients with inhibitors showed greater adherence with regard to the DPR dimension. Additionally, these patients used orthopaedic devices for proper functionality in their daily lives, unsurprisingly because they presented with more difficulties associated with the disease. This finding might be a reason to abandon treatment. However, these patients visit their doctor, they believe that professionals help them to solve their problems, and this promotes adherence. Therefore, a positive therapeutic alliance is relevant for patients to follow treatments. In chronic care, it is difficult to implement treatment without considering the patient's interpretations, preferences, feelings, concerns, needs, values, and social context.[@CIT0029],[@CIT0030]

Patients with a family history of haemophilia showed greater difficulties with treatment. Inheritance is not a guarantee of better control. According to how the past experience has been lived, it may be conditioned for or against the future view of the new generations. In addition, the first effective factor concentrates did not appear until the 1970s and the subsequent emergence of the HIV and HCV infections in the 1980s (especially the latter) caused rejection and distrust among the patients. Patients should follow recommended treatments if they want to be well and have a life of quality. But we cannot forget that adverse circumstances experienced personally or by others may influence patient response. Thus, improving and adapting communication to patients' demands and needs might help to enable a successful cohabitation with the disease and motivate them to change wrong behaviours. Thereby, every day, it is more evident that treatments (prophylaxis or on-demand) should be personalised.[@CIT0031]

Strengths and Limitations {#S0004-S2001}
-------------------------

One limitation of our study might be the ceiling effect regarding the dimensions DT and DPR, which could be improved (specifically, items 14 and 15). Another limitation might be the small sample size. However, the recruitment via personal interview, which facilitated the correct and complete data collection, must be considered. Furthermore, the PWH census of all of Spain via random selection suggests that the data are representative.

Conclusions {#S0005}
===========

The Haemo-Adhaesione scale is a satisfactory measure of patient adherence to haemophilia. Its multidimensional structure favours the inclusion of the objective and subjective aspects implicit in its definition. We believe that the inclusion of the additional measure on the scale regarding patient knowledge about treatment and disease is adequate. Patients with greater adherence are more aware of their symptoms, which favours their involvement in following the guidelines indicated on a regular basis. This scale also discriminates among patients who follow different treatments. Most importantly, it helps professionals consider what action to take for dealing with non-adherence, emphasising that psychosocial aspects condition patient responses to maintain treatment success. The clinical signs of haemophilia are relevant, but new treatments that reduce the number of treatment days and symptoms can lead patients to "forget" the disease and show consequently inadequate adherence. Therefore, these psychosocial aspects play a determining role in adherence.
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[^1]: **Note:** Items in boldface are items finally selected to the scale.

[^2]: **Notes:** Total, Total score in the Haemo-Adhaesione scale; l, number of items in the dimension/total scale.

    **Abbreviations:** AI, Awareness of Illness; SK, Sequelae Knowledge; TD, Treatment Difficulties; DPR, Doctor--Patient Relationship; HPT, Hemorrhagic Process Treatment.

[^3]: **Notes:** \**p* \< 0.05; \*\*\**p .\< 0.001*.

[^4]: **Abbreviations:** AI, Awareness of illness; SK, Sequelae Knowledge; TD, Treatment Difficulties; DPR, Doctor--Patient Relationship; HP, Hemorrhagic Process Treatment.

[^5]: **Notes:** \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001. Total: Total score in the Haemo-Adhaesione scale.

[^6]: **Abbreviations:** AI, Awareness of illness; SK, Sequelae knowledge; TD, Treatment Difficulties; DPR, Doctor--Patient Relationship; HP, Hemorrhagic Process Treatment.

[^7]: **Notes:** \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001. Total: Total score in the Haemo-Adhaesione scale.

    **Abbreviations:** AI, Awareness of Illness; SK, Sequelae Knowledge; TD, Treatment Difficulties; DPR, Doctor--Patient Relationship; HPT, Hemorrhagic Process Treatment.

[^8]: **Notes:** \*An asterisk next to a parameter estimate indicates that it is constrained. In brackets, the ítem number on the original scale of 60 items.

[^9]: **Notes:** \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001. Total: Total score in the Haemo-Adhaesione scale.

[^10]: **Abbreviations:** AI, Awareness of Illness; SK, Sequelae Knowledge; TD, Treatment Difficulties; DPR, Doctor--Patient Relationship; HPT, Hemorrhagic Process Treatment.
